DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registryDan Turner, Frank M. Ruemmele, Jeffrey S. Hyams et al.|Journal of Crohn s and Colitis|2018Cited by 0